Novel Federated Decision Making for Distribution of Anti-SARS-CoV-2 Monoclonal Antibody to Eligible High-Risk Patients

Novel Federated Decision Making for Distribution of Anti-SARS-CoV-2 Monoclonal Antibody to Eligible High-Risk Patients

Context: When the epidemic ¯rst broke out, no speci¯c treatment was available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The urgent need to end this unusual sit uation has resulted in many attempts to deal with SARS-CoV-2. In addition to several types of vaccinations that have...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: AlSereidi, Abeer (author)
مؤلفون آخرون: Qahtan M. Salih, Sarah (author), Mohammed, R. T. (author), A. Zaidan, A. (author), Albayati, Hassan (author), Pamucar, Dragan (author), Albahri, A. S. (author), Zaidan, B. B. (author), Shaalan, Khaled (author), Al-Obaidi, Jameel (author), Albahri, O. S. (author), Alamoodi, Abdulah (author), Abdul Majid, Nazia (author), Garfan, Salem (author), Al-Samarraay, M. S. (author), Jasim, A. N. (author), Baqer, M. J. (author)
منشور في: 2022
الموضوعات:
Anti-SARS-CoV-2; monoclonal antibodies; MCDM; FWZIC; TOPSIS.
الوصول للمادة أونلاين:https://bspace.buid.ac.ae/handle/1234/2782
https://doi.org/10.1142/S021962202250050X.
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

الانترنت

https://bspace.buid.ac.ae/handle/1234/2782
https://doi.org/10.1142/S021962202250050X.

مواد مشابهة